Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07817082
What this trial is testing

Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer With Ultra-Low HER2 Expression
Tianjin Medical University Cancer Institute and Hospital 30
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Not applicableUnknownNCT05834699
What this trial is testing

HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC

Who this might be right for
Breast Cancer
Beijing 302 Hospital 50
Early research (Phase 1)Looking for participantsNCT07383506
What this trial is testing

Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Who this might be right for
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more
Cogent Biosciences, Inc. 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189884
What this trial is testing

Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy

Who this might be right for
Locally Advanced Breast Cancer (LABC)
The First Affiliated Hospital of Xiamen University 33
Testing effectiveness (Phase 2)UnknownNCT05845138
What this trial is testing

SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Who this might be right for
Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 116
Large-scale testing (Phase 3)Temporarily pausedNCT06671912
What this trial is testing

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

Who this might be right for
Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage 1 Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8+4 more
Alliance for Clinical Trials in Oncology 1,556
Large-scale testing (Phase 3)UnknownNCT03507465
What this trial is testing

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Guangdong Provincial People's Hospital 290
Testing effectiveness (Phase 2)Active Not RecruitingNCT06157892
What this trial is testing

Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Who this might be right for
Breast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast Neoplasms+7 more
Seagen, a wholly owned subsidiary of Pfizer 54
Testing effectiveness (Phase 2)Ended earlyNCT00351858
What this trial is testing

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsBreast Cancer
Neovii Biotech 40
Large-scale testing (Phase 3)Study completedNCT01479244
What this trial is testing

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

Who this might be right for
Breast Cancer With Low to Intermediate HER2 Expression
Galena Biopharma, Inc. 758
Not applicableLooking for participantsNCT06830382
What this trial is testing

HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC

Who this might be right for
Breast Cancer Stage IVHER2-low Breast CancerMolecular Imaging
Renske Altena 70
Testing effectiveness (Phase 2)UnknownNCT06411457
What this trial is testing

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 20
Very early researchLooking for participantsNCT06828588
What this trial is testing

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Who this might be right for
Locally Advanced CancerMetastatic CancerHER2+2 more
Vanderbilt-Ingram Cancer Center 30
Testing effectiveness (Phase 2)UnknownNCT05792410
What this trial is testing

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

Who this might be right for
HER2 Low Advanced or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07729046
What this trial is testing

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

Who this might be right for
Metastatic Invasive Breast CancerResistant Breast CancerER+, HER2-, Metastatic Breast Cancer
University of California, San Diego 150
Large-scale testing (Phase 3)Active Not RecruitingNCT05814354
What this trial is testing

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

Who this might be right for
Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 551
Testing effectiveness (Phase 2)Looking for participantsNCT05795101
What this trial is testing

TRUDI: TDXD+Durva in HER2+/Low IBC

Who this might be right for
Invasive Breast CancerInflammatory Breast Cancer Stage IIIHER2-positive Breast Cancer+2 more
Filipa Lynce, MD 63
Not applicableLooking for participantsNCT07613151
What this trial is testing

Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study

Who this might be right for
Lobular Breast Carcinoma
Istituto Oncologico Veneto IRCCS 250
Large-scale testing (Phase 3)Looking for participantsNCT06079983
What this trial is testing

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Who this might be right for
Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 400
Next Page